Xiyuan Yao

Xiyuan Yao

Auto-generated profile, based on publicly available information

Xiyuan Yao

Department of Chemistry, University of Chicago, 5735 S. Ellis Ave., Chicago, Illinois 60637, United States

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
TLTong Lan
Tong Lan
CPCheng Peng
Cheng Peng
XYXiyuan Yao
Xiyuan Yao
RCRachel Shu Ting Chan
Rachel Shu Ting Chan
TWTongyao Wei
Tongyao Wei
BDBryan C. Dickinson
Bryan C. Dickinson

16 September 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XYXiyuan Yao
Xiyuan Yao
NWNoah H. Watkins
Noah H. Watkins
HBHeather Brown-Harding
Heather Brown-Harding
UBUlrich Bierbach
Ulrich Bierbach
Cytotoxic drugs that are mechanistically distinct from current chemotherapies are attractive components of personalized combination regimens for combatting aggressive forms of cancer. To gain insight into the cellular mechanism of a potent platinum–acridine anticancer agent (compound 1), a correlation analysis of NCI-60 compound screening results and gene expression profiles was performed. A plasma membrane transporter, the solute carrier (SLC) human multidrug and toxin extrusion protein 1 (hMATE1, SLC47A1), emerged as the dominant predictor of cancer cell chemosensitivity to the hybrid agent (Pearson correlation analysis, p < 10–5) across a wide range of tissues of origin. The crucial role of hMATE1 was validated in lung adenocarcinoma cells (A549), which expresses high levels of the membrane transporter, using transporter inhibition assays and transient knockdown of the SLC47A1 gene, in conjunction with quantification of intracellular accumulation of compound 1 and cell viability screening. Preliminary data also show that HCT-116 colon cancer cells, in which hMATE1 is epigenetically repressed, can be sensitized to compound 1 by priming the cells with the drugs EPZ-6438 (tazemetostat) and EED226. Collectively, these results suggest that hMATE1 may have applications as a pan-cancer molecular marker to identify and target tumors that are likely to respond to platinum–acridines.

15 September 2025 in Journal of the American Chemical Society
Verified
Journal Article
Open access
XYXiyuan Yao
Xiyuan Yao
KAKanokpol Aphicho
Kanokpol Aphicho
SPShubhashree Pani
Shubhashree Pani
ARAnuchit Rupanya
Anuchit Rupanya
TLTong Lan
Tong Lan
BDBryan C. Dickinson
Bryan C. Dickinson
RNA targeting represents a compelling strategy for addressing challenging therapeutic targets that are otherwise intractable through traditional protein targeting. Revolutionary approaches in RNA-focused small molecule libraries have successfully identified RNA-binding ligands but generally remain limited in diversity and impeded by a dearth of structural insight into RNA and RNA complexes. Cyclic peptides are potential structural mimics of evolutionary RNA-protein interacting motifs and can be massively diversified and selected via genetically encoded libraries, offering a complementary approach. This study introduces genetically encoded thioether cyclic peptide libraries constructed through mRNA display using a dibromoxylene linker and its fluorosulfonyl derivative that can covalently engage RNA nucleophiles. Using an optimized mRNA display workflow for RNA binders, we discovered high affinity, covalent and noncovalent binders for SNCA 5' UTR IRE, the upstream iron-responsive element that post-transcriptionally regulates the expression of α-synuclein, an intrinsically disordered protein implicated in Parkinsonism and related neurodegenerative diseases. Notably, a stringent selection strategy employing "base-paired" target analog counterselection enhanced specificity by deenriching nonspecific electrostatic interactions mediated by polycationic residues. Further engineering hit peptides with an imidazole tag yielded selective RNA degraders in which covalent degraders showed noticeably improved potency from noncovalent counterparts. This work provides a prototype framework for evolution-driven, high-throughput, RNA-targeted drug discovery using cyclic peptides.

1 December 2016 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
Cale FahrenholtzCale Fahrenholtz
Cale Fahrenholtz
SDSong Ding
Song Ding
BBBrian W. Bernish
Brian W. Bernish
MWMariah L. Wright
Mariah L. Wright
YZYe Zheng
Ye Zheng
RSRavi Singh
Ravi Singh

13 December 2018 in Inorganic Chemistry
Verified
Journal Article
Closed access
XYXiyuan Yao
Xiyuan Yao
CTChristopher M. Tracy
Christopher M. Tracy
UBUlrich Bierbach
Ulrich Bierbach

9 October 2023 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
IMIkeer Y. Mancera-Ortiz
Ikeer Y. Mancera-Ortiz
JCJiangxue Chen
Jiangxue Chen
TSTyler A. Slade
Tyler A. Slade
XYXiyuan Yao
Xiyuan Yao
SZShenjie Zhang
Shenjie Zhang
UBUlrich Bierbach
Ulrich Bierbach